TEZSPIRE — Total revenues
Amgen TEZSPIRE — Total revenues decreased by 96.0% to $343M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 95.8%, from $8.15B to $343M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market penetration, successful commercial execution, or expanded clinical indications for the therapy, while a decrease may signal increased competition, patent expirations, or shifts in physician prescribing patterns.
Detailed definition
This metric represents the total gross sales generated by the specific therapeutic product line within the company's por...
Peer comparison
Comparable to product-specific revenue reporting in other biopharmaceutical companies, often benchmarked against consensus estimates for key growth drivers and blockbusters.
amgn_segment_tezspire_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.53B | $6.71B | $6.85B | $6.24B | $42.5M | $6.59B | $42.5M | $6.65B | $42.5M | $6.84B | $42.5M | $6.11B | $96M | $6.99B | $133M | $6.9B | $161M | $8.2B | $177M | $7.45B | $173M | $8.39B | $234M | $8.5B | $269M | $9.09B | $296M | $8.15B | $285M | $9.18B | $342M | $9.56B | $377M | $9.87B | $474M | $8.62B | $343M |
| QoQ Change | — | +2.8% | +2.1% | -8.9% | -99.3% | >999% | -99.4% | >999% | -99.4% | >999% | -99.4% | >999% | -98.4% | >999% | -98.1% | >999% | -97.7% | >999% | -97.8% | >999% | -97.7% | >999% | -97.2% | >999% | -96.8% | >999% | -96.7% | >999% | -96.5% | >999% | -96.3% | >999% | -96.1% | >999% | -95.2% | >999% | -96.0% |
| YoY Change | — | — | — | — | — | +1.0% | -99.3% | -0.8% | -99.4% | -0.1% | -99.4% | -2.1% | -98.5% | +5.9% | -98.0% | +3.8% | -97.6% | +19.8% | -97.4% | +22.0% | -97.2% | +20.1% | -96.7% | +23.2% | -96.1% | +10.9% | -96.4% | +9.4% | -96.2% | +9.4% | -95.9% | +12.4% | -95.6% | +8.6% | -94.8% | +5.8% | -95.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's tezspire — total revenues?
- Amgen (AMGN) reported tezspire — total revenues of $343M in Q1 2026.
- How has Amgen's tezspire — total revenues changed year-over-year?
- Amgen's tezspire — total revenues decreased by 95.8% year-over-year, from $8.15B to $343M.
- What does tezspire — total revenues mean?
- The total revenue generated from sales of the specific therapeutic product.